Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

EZH2 (Enhancer of zeste homolog 2) protein is the enzymatic component of the Polycomb repressive complex 2 (PRC2), which represses gene expression by methylating lysine 27 of histone H3 (H3K27) and regulates cell proliferation and differentiation during embryonic development. Recently, hot-spot mutations of EZH2 were identified in diffused large B-cell lymphomas and follicular lymphomas. To investigate if tumor growth is dependent on the enzymatic activity of EZH2, we developed a potent and selective small molecule inhibitor, EI1, which inhibits the enzymatic activity of EZH2 through direct binding to the Enzyme and competing with the methyl group donor S-Adenosyl methionine. EI1-treated cells exhibit genome-wide loss of H3K27 methylation and activation of PRC2 target genes. Furthermore, inhibition of EZH2 by EI1 in diffused large B-cell lymphomas cells carrying the Y641 mutations results in decreased proliferation, cell cycle arrest, and Apoptosis. These results provide strong validation of EZH2 as a potential therapeutic target for the treatment of Cancer.